nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—hypertension—obesity	0.403	1	CtDrD
Nadolol—ADRB3—obesity	0.169	0.546	CbGaD
Nadolol—ADRB2—Phenylpropanolamine—obesity	0.079	0.463	CbGbCtD
Nadolol—ADRB1—Phenylpropanolamine—obesity	0.0778	0.456	CbGbCtD
Nadolol—ADRB1—obesity	0.0765	0.247	CbGaD
Nadolol—ADRB2—obesity	0.0643	0.208	CbGaD
Nadolol—ABCB1—Cimetidine—obesity	0.0138	0.0807	CbGbCtD
Nadolol—ADRB3—brown adipose tissue—obesity	0.00567	0.669	CbGeAlD
Nadolol—Treprostinil—PPARD—obesity	0.00103	0.328	CrCbGaD
Nadolol—ADRB3—adipose tissue—obesity	0.000765	0.0903	CbGeAlD
Nadolol—ADRB1—cardiovascular system—obesity	0.000355	0.0419	CbGeAlD
Nadolol—ADRB1—adipose tissue—obesity	0.000313	0.0369	CbGeAlD
Nadolol—Sleep disorder—Sibutramine—obesity	0.000272	0.00456	CcSEcCtD
Nadolol—Alopecia—Cimetidine—obesity	0.000269	0.00452	CcSEcCtD
Nadolol—Dry mouth—Phentermine—obesity	0.000267	0.00448	CcSEcCtD
Nadolol—Vision blurred—Diethylpropion—obesity	0.000262	0.00441	CcSEcCtD
Nadolol—Oedema—Phentermine—obesity	0.000261	0.00439	CcSEcCtD
Nadolol—Flatulence—Cimetidine—obesity	0.000261	0.00439	CcSEcCtD
Nadolol—Dry eye—Bupropion—obesity	0.000261	0.00438	CcSEcCtD
Nadolol—Cardiac failure congestive—Sibutramine—obesity	0.000259	0.00436	CcSEcCtD
Nadolol—Nasal congestion—Sibutramine—obesity	0.000258	0.00434	CcSEcCtD
Nadolol—Hypotension—Phenylpropanolamine—obesity	0.000255	0.00429	CcSEcCtD
Nadolol—Libido decreased—Sibutramine—obesity	0.000254	0.00426	CcSEcCtD
Nadolol—Amnesia—Sibutramine—obesity	0.00025	0.0042	CcSEcCtD
Nadolol—Diarrhoea—Methamphetamine—obesity	0.000249	0.00418	CcSEcCtD
Nadolol—Insomnia—Phenylpropanolamine—obesity	0.000247	0.00415	CcSEcCtD
Nadolol—ADRB1—endocrine gland—obesity	0.000243	0.0287	CbGeAlD
Nadolol—Dyspnoea—Phenylpropanolamine—obesity	0.000243	0.00409	CcSEcCtD
Nadolol—Dizziness—Methamphetamine—obesity	0.00024	0.00404	CcSEcCtD
Nadolol—Diarrhoea—Benzphetamine—obesity	0.00024	0.00403	CcSEcCtD
Nadolol—Bupranolol—ADRB3—obesity	0.000239	0.0763	CrCbGaD
Nadolol—Chest pain—Diethylpropion—obesity	0.000237	0.00398	CcSEcCtD
Nadolol—Sleep disorder—Bupropion—obesity	0.000237	0.00398	CcSEcCtD
Nadolol—Insomnia—Phentermine—obesity	0.000236	0.00397	CcSEcCtD
Nadolol—Constipation—Phenylpropanolamine—obesity	0.000233	0.00392	CcSEcCtD
Nadolol—Disturbance in sexual arousal—Sibutramine—obesity	0.000233	0.00392	CcSEcCtD
Nadolol—Dizziness—Benzphetamine—obesity	0.000232	0.0039	CcSEcCtD
Nadolol—Dry mouth—Diethylpropion—obesity	0.000232	0.0039	CcSEcCtD
Nadolol—Affect lability—Sibutramine—obesity	0.000231	0.00389	CcSEcCtD
Nadolol—Dyspepsia—Phentermine—obesity	0.00023	0.00386	CcSEcCtD
Nadolol—Disorientation—Bupropion—obesity	0.000229	0.00385	CcSEcCtD
Nadolol—Fatigue—Phentermine—obesity	0.000225	0.00378	CcSEcCtD
Nadolol—Nasal congestion—Bupropion—obesity	0.000225	0.00378	CcSEcCtD
Nadolol—Constipation—Phentermine—obesity	0.000223	0.00375	CcSEcCtD
Nadolol—Mood swings—Sibutramine—obesity	0.000223	0.00374	CcSEcCtD
Nadolol—Dry skin—Orlistat—obesity	0.000223	0.00374	CcSEcCtD
Nadolol—Libido decreased—Bupropion—obesity	0.000221	0.00371	CcSEcCtD
Nadolol—Hyperhidrosis—Diethylpropion—obesity	0.00022	0.00369	CcSEcCtD
Nadolol—Diarrhoea—Phendimetrazine—obesity	0.000219	0.00367	CcSEcCtD
Nadolol—Amnesia—Bupropion—obesity	0.000218	0.00367	CcSEcCtD
Nadolol—Visual disturbance—Bupropion—obesity	0.000216	0.00363	CcSEcCtD
Nadolol—Dry skin—Sibutramine—obesity	0.000215	0.00362	CcSEcCtD
Nadolol—Gastritis—Orlistat—obesity	0.000215	0.00361	CcSEcCtD
Nadolol—Abdominal distension—Orlistat—obesity	0.000211	0.00355	CcSEcCtD
Nadolol—Dizziness—Phendimetrazine—obesity	0.000211	0.00355	CcSEcCtD
Nadolol—Lethargy—Bupropion—obesity	0.000209	0.00351	CcSEcCtD
Nadolol—Nausea—Benzphetamine—obesity	0.000208	0.0035	CcSEcCtD
Nadolol—Gastritis—Sibutramine—obesity	0.000208	0.0035	CcSEcCtD
Nadolol—Bronchospasm—Orlistat—obesity	0.000207	0.00347	CcSEcCtD
Nadolol—Insomnia—Diethylpropion—obesity	0.000206	0.00345	CcSEcCtD
Nadolol—Diplopia—Bupropion—obesity	0.000205	0.00344	CcSEcCtD
Nadolol—Abdominal distension—Sibutramine—obesity	0.000205	0.00344	CcSEcCtD
Nadolol—Disturbance in sexual arousal—Bupropion—obesity	0.000203	0.00342	CcSEcCtD
Nadolol—Dyspnoea—Diethylpropion—obesity	0.000203	0.0034	CcSEcCtD
Nadolol—Affect lability—Bupropion—obesity	0.000202	0.00339	CcSEcCtD
Nadolol—Abdominal discomfort—Orlistat—obesity	0.000201	0.00338	CcSEcCtD
Nadolol—Dyspepsia—Diethylpropion—obesity	0.0002	0.00336	CcSEcCtD
Nadolol—Irritability—Bupropion—obesity	0.000196	0.00329	CcSEcCtD
Nadolol—Constipation—Diethylpropion—obesity	0.000194	0.00327	CcSEcCtD
Nadolol—Mood swings—Bupropion—obesity	0.000194	0.00326	CcSEcCtD
Nadolol—Dysarthria—Topiramate—obesity	0.00019	0.0032	CcSEcCtD
Nadolol—Hepatic enzyme increased—Topiramate—obesity	0.00019	0.0032	CcSEcCtD
Nadolol—Nausea—Phendimetrazine—obesity	0.00019	0.00319	CcSEcCtD
Nadolol—Dry skin—Bupropion—obesity	0.000188	0.00316	CcSEcCtD
Nadolol—Asthenia—Phentermine—obesity	0.000187	0.00315	CcSEcCtD
Nadolol—Erectile dysfunction—Sibutramine—obesity	0.000187	0.00314	CcSEcCtD
Nadolol—Depression—Orlistat—obesity	0.000187	0.00314	CcSEcCtD
Nadolol—Fatigue—Cimetidine—obesity	0.000186	0.00313	CcSEcCtD
Nadolol—Atrioventricular block—Topiramate—obesity	0.000185	0.00312	CcSEcCtD
Nadolol—Constipation—Cimetidine—obesity	0.000185	0.00311	CcSEcCtD
Nadolol—Weight increased—Sibutramine—obesity	0.000185	0.00311	CcSEcCtD
Nadolol—Gastritis—Bupropion—obesity	0.000181	0.00305	CcSEcCtD
Nadolol—Depression—Sibutramine—obesity	0.000181	0.00304	CcSEcCtD
Nadolol—Dizziness—Phenylpropanolamine—obesity	0.000181	0.00303	CcSEcCtD
Nadolol—Diarrhoea—Phentermine—obesity	0.000179	0.003	CcSEcCtD
Nadolol—Abdominal distension—Bupropion—obesity	0.000178	0.003	CcSEcCtD
Nadolol—Conjunctivitis—Sibutramine—obesity	0.000176	0.00296	CcSEcCtD
Nadolol—Bronchospasm—Bupropion—obesity	0.000174	0.00293	CcSEcCtD
Nadolol—Sweating—Sibutramine—obesity	0.000174	0.00292	CcSEcCtD
Nadolol—Vomiting—Phenylpropanolamine—obesity	0.000174	0.00292	CcSEcCtD
Nadolol—Dizziness—Phentermine—obesity	0.000173	0.0029	CcSEcCtD
Nadolol—Rash—Phenylpropanolamine—obesity	0.000172	0.00289	CcSEcCtD
Nadolol—Dermatitis—Phenylpropanolamine—obesity	0.000172	0.00289	CcSEcCtD
Nadolol—Body temperature increased—Cimetidine—obesity	0.000171	0.00287	CcSEcCtD
Nadolol—Fluid retention—Topiramate—obesity	0.000171	0.00287	CcSEcCtD
Nadolol—Abdominal discomfort—Bupropion—obesity	0.00017	0.00285	CcSEcCtD
Nadolol—Pirbuterol—ADRB1—obesity	0.000168	0.0535	CrCbGaD
Nadolol—Dry eye—Topiramate—obesity	0.000166	0.00279	CcSEcCtD
Nadolol—Vomiting—Phentermine—obesity	0.000166	0.00279	CcSEcCtD
Nadolol—Bradycardia—Sibutramine—obesity	0.000166	0.00278	CcSEcCtD
Nadolol—Rash—Phentermine—obesity	0.000165	0.00277	CcSEcCtD
Nadolol—Dermatitis—Phentermine—obesity	0.000165	0.00277	CcSEcCtD
Nadolol—ABCB1—islet of Langerhans—obesity	0.000164	0.0194	CbGeAlD
Nadolol—Erectile dysfunction—Bupropion—obesity	0.000163	0.00274	CcSEcCtD
Nadolol—Nausea—Phenylpropanolamine—obesity	0.000162	0.00272	CcSEcCtD
Nadolol—Weight increased—Bupropion—obesity	0.000161	0.00271	CcSEcCtD
Nadolol—Pindolol—ADRB3—obesity	0.000157	0.0503	CrCbGaD
Nadolol—Visual impairment—Sibutramine—obesity	0.000157	0.00263	CcSEcCtD
Nadolol—Diarrhoea—Diethylpropion—obesity	0.000156	0.00261	CcSEcCtD
Nadolol—ABCB1—respiratory system—obesity	0.000155	0.0183	CbGeAlD
Nadolol—Nausea—Phentermine—obesity	0.000155	0.00261	CcSEcCtD
Nadolol—Asthenia—Cimetidine—obesity	0.000155	0.00261	CcSEcCtD
Nadolol—Conjunctivitis—Bupropion—obesity	0.000154	0.00258	CcSEcCtD
Nadolol—Tinnitus—Sibutramine—obesity	0.000152	0.00255	CcSEcCtD
Nadolol—Sweating—Bupropion—obesity	0.000151	0.00254	CcSEcCtD
Nadolol—Sleep disorder—Topiramate—obesity	0.000151	0.00253	CcSEcCtD
Nadolol—Dizziness—Diethylpropion—obesity	0.00015	0.00253	CcSEcCtD
Nadolol—Levobunolol—ADRB1—obesity	0.000149	0.0477	CrCbGaD
Nadolol—Alopecia—Orlistat—obesity	0.000148	0.0025	CcSEcCtD
Nadolol—Diarrhoea—Cimetidine—obesity	0.000148	0.00249	CcSEcCtD
Nadolol—Disorientation—Topiramate—obesity	0.000146	0.00245	CcSEcCtD
Nadolol—Vomiting—Diethylpropion—obesity	0.000145	0.00243	CcSEcCtD
Nadolol—Flatulence—Orlistat—obesity	0.000144	0.00242	CcSEcCtD
Nadolol—Alopecia—Sibutramine—obesity	0.000144	0.00241	CcSEcCtD
Nadolol—Nasal congestion—Topiramate—obesity	0.000143	0.00241	CcSEcCtD
Nadolol—Rash—Diethylpropion—obesity	0.000143	0.00241	CcSEcCtD
Nadolol—Dermatitis—Diethylpropion—obesity	0.000143	0.00241	CcSEcCtD
Nadolol—Dizziness—Cimetidine—obesity	0.000143	0.0024	CcSEcCtD
Nadolol—Hallucination—Bupropion—obesity	0.000141	0.00237	CcSEcCtD
Nadolol—Pirbuterol—ADRB2—obesity	0.000141	0.045	CrCbGaD
Nadolol—Libido decreased—Topiramate—obesity	0.000141	0.00237	CcSEcCtD
Nadolol—Flatulence—Sibutramine—obesity	0.00014	0.00234	CcSEcCtD
Nadolol—Amnesia—Topiramate—obesity	0.000139	0.00234	CcSEcCtD
Nadolol—Vision blurred—Orlistat—obesity	0.000138	0.00232	CcSEcCtD
Nadolol—Visual disturbance—Topiramate—obesity	0.000138	0.00232	CcSEcCtD
Nadolol—Vomiting—Cimetidine—obesity	0.000137	0.00231	CcSEcCtD
Nadolol—Visual impairment—Bupropion—obesity	0.000137	0.0023	CcSEcCtD
Nadolol—Rash—Cimetidine—obesity	0.000136	0.00229	CcSEcCtD
Nadolol—Dermatitis—Cimetidine—obesity	0.000136	0.00229	CcSEcCtD
Nadolol—Nausea—Diethylpropion—obesity	0.000135	0.00227	CcSEcCtD
Nadolol—Vision blurred—Sibutramine—obesity	0.000133	0.00224	CcSEcCtD
Nadolol—Lethargy—Topiramate—obesity	0.000133	0.00224	CcSEcCtD
Nadolol—Tinnitus—Bupropion—obesity	0.000132	0.00222	CcSEcCtD
Nadolol—Diplopia—Topiramate—obesity	0.000131	0.00219	CcSEcCtD
Nadolol—ABCB1—adrenal cortex—obesity	0.00013	0.0154	CbGeAlD
Nadolol—Disturbance in sexual arousal—Topiramate—obesity	0.00013	0.00218	CcSEcCtD
Nadolol—Affect lability—Topiramate—obesity	0.000129	0.00216	CcSEcCtD
Nadolol—Nausea—Cimetidine—obesity	0.000128	0.00216	CcSEcCtD
Nadolol—Cough—Orlistat—obesity	0.000128	0.00214	CcSEcCtD
Nadolol—Carteolol—ADRB1—obesity	0.000127	0.0406	CrCbGaD
Nadolol—Syncope—Sibutramine—obesity	0.000127	0.00213	CcSEcCtD
Nadolol—Levobunolol—ADRB2—obesity	0.000126	0.0401	CrCbGaD
Nadolol—Alopecia—Bupropion—obesity	0.000125	0.00211	CcSEcCtD
Nadolol—Irritability—Topiramate—obesity	0.000125	0.00209	CcSEcCtD
Nadolol—Chest pain—Orlistat—obesity	0.000125	0.00209	CcSEcCtD
Nadolol—Loss of consciousness—Sibutramine—obesity	0.000124	0.00209	CcSEcCtD
Nadolol—Mood swings—Topiramate—obesity	0.000124	0.00208	CcSEcCtD
Nadolol—Cough—Sibutramine—obesity	0.000124	0.00208	CcSEcCtD
Nadolol—Hypertension—Sibutramine—obesity	0.000122	0.00205	CcSEcCtD
Nadolol—Dry mouth—Orlistat—obesity	0.000122	0.00205	CcSEcCtD
Nadolol—Flatulence—Bupropion—obesity	0.000122	0.00204	CcSEcCtD
Nadolol—Chest pain—Sibutramine—obesity	0.000121	0.00203	CcSEcCtD
Nadolol—Oedema—Orlistat—obesity	0.000119	0.00201	CcSEcCtD
Nadolol—ABCB1—cardiovascular system—obesity	0.000119	0.014	CbGeAlD
Nadolol—Dry mouth—Sibutramine—obesity	0.000118	0.00198	CcSEcCtD
Nadolol—Vision blurred—Bupropion—obesity	0.000116	0.00195	CcSEcCtD
Nadolol—Gastritis—Topiramate—obesity	0.000116	0.00194	CcSEcCtD
Nadolol—Oedema—Sibutramine—obesity	0.000116	0.00194	CcSEcCtD
Nadolol—Hyperhidrosis—Orlistat—obesity	0.000115	0.00194	CcSEcCtD
Nadolol—Shock—Sibutramine—obesity	0.000114	0.00191	CcSEcCtD
Nadolol—Abdominal distension—Topiramate—obesity	0.000114	0.00191	CcSEcCtD
Nadolol—Hyperhidrosis—Sibutramine—obesity	0.000112	0.00188	CcSEcCtD
Nadolol—Penbutolol—HTR1B—obesity	0.000112	0.0357	CrCbGaD
Nadolol—Syncope—Bupropion—obesity	0.000111	0.00186	CcSEcCtD
Nadolol—Anorexia—Sibutramine—obesity	0.00011	0.00185	CcSEcCtD
Nadolol—Loss of consciousness—Bupropion—obesity	0.000108	0.00182	CcSEcCtD
Nadolol—Abdominal discomfort—Topiramate—obesity	0.000108	0.00182	CcSEcCtD
Nadolol—Insomnia—Orlistat—obesity	0.000108	0.00181	CcSEcCtD
Nadolol—Bupranolol—ADRB1—obesity	0.000108	0.0345	CrCbGaD
Nadolol—Hypotension—Sibutramine—obesity	0.000108	0.00181	CcSEcCtD
Nadolol—Cough—Bupropion—obesity	0.000108	0.00181	CcSEcCtD
Nadolol—Paraesthesia—Orlistat—obesity	0.000107	0.0018	CcSEcCtD
Nadolol—Carteolol—ADRB2—obesity	0.000107	0.0341	CrCbGaD
Nadolol—Hypertension—Bupropion—obesity	0.000107	0.00179	CcSEcCtD
Nadolol—ABCB1—pituitary gland—obesity	0.000105	0.0124	CbGeAlD
Nadolol—Dyspepsia—Orlistat—obesity	0.000105	0.00177	CcSEcCtD
Nadolol—Chest pain—Bupropion—obesity	0.000105	0.00177	CcSEcCtD
Nadolol—ABCB1—adipose tissue—obesity	0.000105	0.0124	CbGeAlD
Nadolol—Insomnia—Sibutramine—obesity	0.000105	0.00176	CcSEcCtD
Nadolol—Erectile dysfunction—Topiramate—obesity	0.000104	0.00175	CcSEcCtD
Nadolol—Decreased appetite—Orlistat—obesity	0.000104	0.00174	CcSEcCtD
Nadolol—Paraesthesia—Sibutramine—obesity	0.000104	0.00174	CcSEcCtD
Nadolol—Dyspnoea—Sibutramine—obesity	0.000103	0.00173	CcSEcCtD
Nadolol—Fatigue—Orlistat—obesity	0.000103	0.00173	CcSEcCtD
Nadolol—Dry mouth—Bupropion—obesity	0.000103	0.00173	CcSEcCtD
Nadolol—Weight increased—Topiramate—obesity	0.000103	0.00173	CcSEcCtD
Nadolol—Pain—Orlistat—obesity	0.000102	0.00172	CcSEcCtD
Nadolol—Dyspepsia—Sibutramine—obesity	0.000102	0.00171	CcSEcCtD
Nadolol—Salbutamol—ADRB1—obesity	0.000102	0.0324	CrCbGaD
Nadolol—Oedema—Bupropion—obesity	0.000101	0.00169	CcSEcCtD
Nadolol—Decreased appetite—Sibutramine—obesity	0.0001	0.00169	CcSEcCtD
Nadolol—Depression—Topiramate—obesity	0.0001	0.00169	CcSEcCtD
Nadolol—Shock—Bupropion—obesity	9.91e-05	0.00167	CcSEcCtD
Nadolol—Constipation—Sibutramine—obesity	9.88e-05	0.00166	CcSEcCtD
Nadolol—Pain—Sibutramine—obesity	9.88e-05	0.00166	CcSEcCtD
Nadolol—Penbutolol—ADRB1—obesity	9.88e-05	0.0315	CrCbGaD
Nadolol—ABCB1—digestive system—obesity	9.87e-05	0.0116	CbGeAlD
Nadolol—Conjunctivitis—Topiramate—obesity	9.78e-05	0.00164	CcSEcCtD
Nadolol—Hyperhidrosis—Bupropion—obesity	9.74e-05	0.00164	CcSEcCtD
Nadolol—Anorexia—Bupropion—obesity	9.6e-05	0.00161	CcSEcCtD
Nadolol—Body temperature increased—Orlistat—obesity	9.44e-05	0.00159	CcSEcCtD
Nadolol—Hypotension—Bupropion—obesity	9.41e-05	0.00158	CcSEcCtD
Nadolol—ABCB1—adrenal gland—obesity	9.4e-05	0.0111	CbGeAlD
Nadolol—Agranulocytosis—Topiramate—obesity	9.39e-05	0.00158	CcSEcCtD
Nadolol—Bradycardia—Topiramate—obesity	9.2e-05	0.00155	CcSEcCtD
Nadolol—Body temperature increased—Sibutramine—obesity	9.13e-05	0.00153	CcSEcCtD
Nadolol—Insomnia—Bupropion—obesity	9.11e-05	0.00153	CcSEcCtD
Nadolol—Bupranolol—ADRB2—obesity	9.08e-05	0.029	CrCbGaD
Nadolol—Paraesthesia—Bupropion—obesity	9.05e-05	0.00152	CcSEcCtD
Nadolol—Hallucination—Topiramate—obesity	8.99e-05	0.00151	CcSEcCtD
Nadolol—Dyspnoea—Bupropion—obesity	8.98e-05	0.00151	CcSEcCtD
Nadolol—Dyspepsia—Bupropion—obesity	8.87e-05	0.00149	CcSEcCtD
Nadolol—Decreased appetite—Bupropion—obesity	8.76e-05	0.00147	CcSEcCtD
Nadolol—Visual impairment—Topiramate—obesity	8.71e-05	0.00146	CcSEcCtD
Nadolol—Fatigue—Bupropion—obesity	8.68e-05	0.00146	CcSEcCtD
Nadolol—Constipation—Bupropion—obesity	8.61e-05	0.00145	CcSEcCtD
Nadolol—Pain—Bupropion—obesity	8.61e-05	0.00145	CcSEcCtD
Nadolol—Asthenia—Orlistat—obesity	8.57e-05	0.00144	CcSEcCtD
Nadolol—Salbutamol—ADRB2—obesity	8.54e-05	0.0273	CrCbGaD
Nadolol—Pruritus—Orlistat—obesity	8.45e-05	0.00142	CcSEcCtD
Nadolol—Tinnitus—Topiramate—obesity	8.42e-05	0.00142	CcSEcCtD
Nadolol—Penbutolol—ADRB2—obesity	8.31e-05	0.0265	CrCbGaD
Nadolol—Asthenia—Sibutramine—obesity	8.29e-05	0.00139	CcSEcCtD
Nadolol—Pruritus—Sibutramine—obesity	8.17e-05	0.00137	CcSEcCtD
Nadolol—Diarrhoea—Orlistat—obesity	8.17e-05	0.00137	CcSEcCtD
Nadolol—ABCB1—endocrine gland—obesity	8.16e-05	0.00962	CbGeAlD
Nadolol—Pindolol—HTR1B—obesity	8.05e-05	0.0257	CrCbGaD
Nadolol—Alopecia—Topiramate—obesity	7.98e-05	0.00134	CcSEcCtD
Nadolol—Body temperature increased—Bupropion—obesity	7.96e-05	0.00134	CcSEcCtD
Nadolol—Diarrhoea—Sibutramine—obesity	7.91e-05	0.00133	CcSEcCtD
Nadolol—Dizziness—Orlistat—obesity	7.9e-05	0.00133	CcSEcCtD
Nadolol—Flatulence—Topiramate—obesity	7.75e-05	0.0013	CcSEcCtD
Nadolol—Dizziness—Sibutramine—obesity	7.64e-05	0.00128	CcSEcCtD
Nadolol—Vomiting—Orlistat—obesity	7.59e-05	0.00128	CcSEcCtD
Nadolol—Rash—Orlistat—obesity	7.53e-05	0.00126	CcSEcCtD
Nadolol—Dermatitis—Orlistat—obesity	7.52e-05	0.00126	CcSEcCtD
Nadolol—Vision blurred—Topiramate—obesity	7.41e-05	0.00125	CcSEcCtD
Nadolol—ABCB1—liver—obesity	7.35e-05	0.00868	CbGeAlD
Nadolol—Vomiting—Sibutramine—obesity	7.35e-05	0.00123	CcSEcCtD
Nadolol—Rash—Sibutramine—obesity	7.29e-05	0.00122	CcSEcCtD
Nadolol—Dermatitis—Sibutramine—obesity	7.28e-05	0.00122	CcSEcCtD
Nadolol—Asthenia—Bupropion—obesity	7.23e-05	0.00121	CcSEcCtD
Nadolol—Pruritus—Bupropion—obesity	7.13e-05	0.0012	CcSEcCtD
Nadolol—Pindolol—ADRB1—obesity	7.12e-05	0.0227	CrCbGaD
Nadolol—Nausea—Orlistat—obesity	7.09e-05	0.00119	CcSEcCtD
Nadolol—Syncope—Topiramate—obesity	7.05e-05	0.00118	CcSEcCtD
Nadolol—Loss of consciousness—Topiramate—obesity	6.91e-05	0.00116	CcSEcCtD
Nadolol—Diarrhoea—Bupropion—obesity	6.89e-05	0.00116	CcSEcCtD
Nadolol—Nausea—Sibutramine—obesity	6.86e-05	0.00115	CcSEcCtD
Nadolol—Cough—Topiramate—obesity	6.86e-05	0.00115	CcSEcCtD
Nadolol—Hypertension—Topiramate—obesity	6.79e-05	0.00114	CcSEcCtD
Nadolol—Chest pain—Topiramate—obesity	6.69e-05	0.00112	CcSEcCtD
Nadolol—Dizziness—Bupropion—obesity	6.66e-05	0.00112	CcSEcCtD
Nadolol—Dry mouth—Topiramate—obesity	6.55e-05	0.0011	CcSEcCtD
Nadolol—Oedema—Topiramate—obesity	6.42e-05	0.00108	CcSEcCtD
Nadolol—Vomiting—Bupropion—obesity	6.4e-05	0.00108	CcSEcCtD
Nadolol—Rash—Bupropion—obesity	6.35e-05	0.00107	CcSEcCtD
Nadolol—Dermatitis—Bupropion—obesity	6.35e-05	0.00107	CcSEcCtD
Nadolol—Shock—Topiramate—obesity	6.31e-05	0.00106	CcSEcCtD
Nadolol—Hyperhidrosis—Topiramate—obesity	6.2e-05	0.00104	CcSEcCtD
Nadolol—Anorexia—Topiramate—obesity	6.12e-05	0.00103	CcSEcCtD
Nadolol—Hypotension—Topiramate—obesity	6e-05	0.00101	CcSEcCtD
Nadolol—Pindolol—ADRB2—obesity	5.99e-05	0.0191	CrCbGaD
Nadolol—Nausea—Bupropion—obesity	5.98e-05	0.00101	CcSEcCtD
Nadolol—Insomnia—Topiramate—obesity	5.8e-05	0.000975	CcSEcCtD
Nadolol—Paraesthesia—Topiramate—obesity	5.76e-05	0.000968	CcSEcCtD
Nadolol—Dyspnoea—Topiramate—obesity	5.72e-05	0.000961	CcSEcCtD
Nadolol—Dyspepsia—Topiramate—obesity	5.65e-05	0.000949	CcSEcCtD
Nadolol—Decreased appetite—Topiramate—obesity	5.58e-05	0.000937	CcSEcCtD
Nadolol—Fatigue—Topiramate—obesity	5.53e-05	0.00093	CcSEcCtD
Nadolol—Pain—Topiramate—obesity	5.49e-05	0.000922	CcSEcCtD
Nadolol—Constipation—Topiramate—obesity	5.49e-05	0.000922	CcSEcCtD
Nadolol—Body temperature increased—Topiramate—obesity	5.07e-05	0.000852	CcSEcCtD
Nadolol—Asthenia—Topiramate—obesity	4.6e-05	0.000774	CcSEcCtD
Nadolol—Pruritus—Topiramate—obesity	4.54e-05	0.000763	CcSEcCtD
Nadolol—Diarrhoea—Topiramate—obesity	4.39e-05	0.000738	CcSEcCtD
Nadolol—Dizziness—Topiramate—obesity	4.24e-05	0.000713	CcSEcCtD
Nadolol—Vomiting—Topiramate—obesity	4.08e-05	0.000686	CcSEcCtD
Nadolol—Rash—Topiramate—obesity	4.05e-05	0.00068	CcSEcCtD
Nadolol—Dermatitis—Topiramate—obesity	4.04e-05	0.000679	CcSEcCtD
Nadolol—Nausea—Topiramate—obesity	3.81e-05	0.000641	CcSEcCtD
Nadolol—ADRB3—Signaling Pathways—PRKCB—obesity	5.13e-06	0.000114	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SREBF2—obesity	5.11e-06	0.000113	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HK1—obesity	5.11e-06	0.000113	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CNR1—obesity	5.08e-06	0.000113	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—BAD—obesity	5.07e-06	0.000112	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—POMC—obesity	5.05e-06	0.000112	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—F2—obesity	5.04e-06	0.000112	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PRKCB—obesity	5.04e-06	0.000112	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—obesity	4.99e-06	0.000111	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TCF7L2—obesity	4.99e-06	0.000111	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CNR1—obesity	4.97e-06	0.00011	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AKT2—obesity	4.97e-06	0.00011	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—DRD2—obesity	4.95e-06	0.00011	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LPA—obesity	4.94e-06	0.000109	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CG—obesity	4.93e-06	0.000109	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CG—obesity	4.91e-06	0.000109	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GCG—obesity	4.9e-06	0.000109	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTPN1—obesity	4.9e-06	0.000109	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TCF7L2—obesity	4.88e-06	0.000108	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AKT2—obesity	4.86e-06	0.000108	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IRS1—obesity	4.85e-06	0.000108	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—DRD2—obesity	4.85e-06	0.000108	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LPIN1—obesity	4.83e-06	0.000107	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CG—obesity	4.82e-06	0.000107	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTPN1—obesity	4.8e-06	0.000106	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GCG—obesity	4.8e-06	0.000106	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CD—obesity	4.77e-06	0.000106	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOA5—obesity	4.73e-06	0.000105	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—POMC—obesity	4.69e-06	0.000104	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PRL—obesity	4.68e-06	0.000104	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—POMC—obesity	4.67e-06	0.000104	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CD—obesity	4.67e-06	0.000104	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—INS—obesity	4.64e-06	0.000103	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—STK11—obesity	4.61e-06	0.000102	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCL2—obesity	4.59e-06	0.000102	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—POMC—obesity	4.59e-06	0.000102	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PRL—obesity	4.58e-06	0.000102	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCL2—obesity	4.57e-06	0.000101	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PLG—obesity	4.56e-06	0.000101	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—RHOA—obesity	4.55e-06	0.000101	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—obesity	4.55e-06	0.000101	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CLOCK—obesity	4.51e-06	0.0001	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC22A1—obesity	4.51e-06	0.0001	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—PPARA—obesity	4.51e-06	0.0001	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—STK11—obesity	4.51e-06	0.0001	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AKT2—obesity	4.51e-06	0.0001	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3R1—obesity	4.51e-06	0.0001	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IGF1—obesity	4.49e-06	9.96e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCL2—obesity	4.49e-06	9.96e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AKT2—obesity	4.49e-06	9.96e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PLG—obesity	4.46e-06	9.9e-05	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—RHOA—obesity	4.45e-06	9.88e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FOXO3—obesity	4.45e-06	9.87e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADRB2—obesity	4.44e-06	9.85e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AKT2—obesity	4.41e-06	9.79e-05	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3R1—obesity	4.41e-06	9.78e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SULT2A1—obesity	4.4e-06	9.76e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GLP1R—obesity	4.4e-06	9.76e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SOCS1—obesity	4.37e-06	9.7e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FOXO3—obesity	4.35e-06	9.66e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CD—obesity	4.33e-06	9.61e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—DPYD—obesity	4.33e-06	9.6e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SOCS3—obesity	4.32e-06	9.58e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CD—obesity	4.31e-06	9.57e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SOCS1—obesity	4.28e-06	9.49e-05	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PIK3CA—obesity	4.27e-06	9.48e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SERPINE1—obesity	4.27e-06	9.46e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CD—obesity	4.24e-06	9.4e-05	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—APOA1—obesity	4.23e-06	9.39e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GNB3—obesity	4.23e-06	9.38e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SOCS3—obesity	4.22e-06	9.37e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—TYK2—obesity	4.17e-06	9.25e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PRKAR2B—obesity	4.17e-06	9.24e-05	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CB—obesity	4.16e-06	9.23e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IGF2—obesity	4.15e-06	9.21e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TYK2—obesity	4.15e-06	9.2e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—DCN—obesity	4.14e-06	9.18e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GNB3—obesity	4.14e-06	9.17e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—RHOA—obesity	4.13e-06	9.17e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GNAS—obesity	4.12e-06	9.13e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—RHOA—obesity	4.11e-06	9.13e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3R1—obesity	4.09e-06	9.08e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—TYK2—obesity	4.08e-06	9.05e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NOS3—obesity	4.07e-06	9.03e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3R1—obesity	4.07e-06	9.03e-05	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CB—obesity	4.07e-06	9.03e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IGF2—obesity	4.06e-06	9.01e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—RHOA—obesity	4.04e-06	8.97e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APOB—obesity	4.03e-06	8.94e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GNAS—obesity	4.03e-06	8.93e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CPT1A—obesity	4.02e-06	8.93e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3R1—obesity	4e-06	8.88e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NAMPT—obesity	3.95e-06	8.75e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APOB—obesity	3.94e-06	8.75e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCL5—obesity	3.94e-06	8.73e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LIPC—obesity	3.92e-06	8.7e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GCK—obesity	3.92e-06	8.7e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOC3—obesity	3.9e-06	8.64e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PIK3CA—obesity	3.88e-06	8.6e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCL5—obesity	3.85e-06	8.54e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LPL—obesity	3.85e-06	8.54e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FOXO1—obesity	3.82e-06	8.48e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RPS6KB1—obesity	3.81e-06	8.46e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CETP—obesity	3.78e-06	8.39e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CB—obesity	3.78e-06	8.38e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LPL—obesity	3.77e-06	8.35e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MTOR—obesity	3.76e-06	8.34e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CB—obesity	3.76e-06	8.34e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SDC1—obesity	3.74e-06	8.3e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FOXO1—obesity	3.74e-06	8.29e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RPS6KB1—obesity	3.73e-06	8.28e-05	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—obesity	3.71e-06	8.24e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CB—obesity	3.69e-06	8.2e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKR1C3—obesity	3.68e-06	8.16e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SCARB1—obesity	3.62e-06	8.04e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PRKCD—obesity	3.55e-06	7.87e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SREBF1—obesity	3.52e-06	7.8e-05	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—AKT1—obesity	3.49e-06	7.74e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HTR2A—obesity	3.47e-06	7.7e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PRKCD—obesity	3.47e-06	7.7e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—C3—obesity	3.47e-06	7.69e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6—obesity	3.43e-06	7.62e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GOT2—obesity	3.42e-06	7.59e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HTR2A—obesity	3.39e-06	7.53e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—C3—obesity	3.39e-06	7.52e-05	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ALB—obesity	3.35e-06	7.44e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—FASN—obesity	3.35e-06	7.43e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—BCHE—obesity	3.33e-06	7.4e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IRS2—obesity	3.3e-06	7.31e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AGT—obesity	3.29e-06	7.3e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MMP9—obesity	3.27e-06	7.25e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LEP—obesity	3.23e-06	7.16e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APOE—obesity	3.23e-06	7.16e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IRS2—obesity	3.22e-06	7.15e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AGT—obesity	3.22e-06	7.15e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP2E1—obesity	3.22e-06	7.14e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CAV1—obesity	3.2e-06	7.09e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APOA1—obesity	3.19e-06	7.07e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NQO1—obesity	3.18e-06	7.06e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAPK8—obesity	3.18e-06	7.05e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—AKT1—obesity	3.17e-06	7.03e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APOE—obesity	3.16e-06	7e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LEP—obesity	3.16e-06	7e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CAV1—obesity	3.13e-06	6.94e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APOA1—obesity	3.12e-06	6.92e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ESR1—obesity	3.08e-06	6.83e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC2A4—obesity	3.05e-06	6.76e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GCG—obesity	3.05e-06	6.76e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PRKCB—obesity	3.04e-06	6.75e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—F2—obesity	3.04e-06	6.75e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ESR1—obesity	3.01e-06	6.68e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYCS—obesity	3.01e-06	6.68e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—BAD—obesity	3.01e-06	6.67e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—F2—obesity	2.98e-06	6.6e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PRKCB—obesity	2.98e-06	6.6e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GOT1—obesity	2.95e-06	6.55e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GGT1—obesity	2.95e-06	6.55e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—BAD—obesity	2.94e-06	6.52e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CG—obesity	2.91e-06	6.46e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NCOA1—obesity	2.91e-06	6.45e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—STAT3—obesity	2.9e-06	6.44e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IRS1—obesity	2.88e-06	6.38e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—STK11—obesity	2.87e-06	6.36e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP19A1—obesity	2.87e-06	6.36e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CG—obesity	2.85e-06	6.32e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IRS1—obesity	2.82e-06	6.25e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—POMC—obesity	2.77e-06	6.15e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—INS—obesity	2.76e-06	6.11e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCL2—obesity	2.71e-06	6.02e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—POMC—obesity	2.71e-06	6.01e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MYC—obesity	2.7e-06	5.99e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—INS—obesity	2.7e-06	5.98e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TGFB1—obesity	2.69e-06	5.97e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IGF1—obesity	2.67e-06	5.91e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—COMT—obesity	2.67e-06	5.91e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKT2—obesity	2.66e-06	5.91e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCL2—obesity	2.65e-06	5.88e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPARGC1A—obesity	2.63e-06	5.83e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GNB3—obesity	2.63e-06	5.83e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HMOX1—obesity	2.62e-06	5.8e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IGF1—obesity	2.61e-06	5.79e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKT2—obesity	2.61e-06	5.78e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CD—obesity	2.56e-06	5.68e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GNAS—obesity	2.56e-06	5.68e-05	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CA—obesity	2.54e-06	5.62e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SERPINE1—obesity	2.53e-06	5.62e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOB—obesity	2.51e-06	5.56e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CD—obesity	2.5e-06	5.55e-05	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CA—obesity	2.48e-06	5.5e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SERPINE1—obesity	2.48e-06	5.49e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TYK2—obesity	2.46e-06	5.46e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RHOA—obesity	2.44e-06	5.42e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOS3—obesity	2.42e-06	5.36e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3R1—obesity	2.42e-06	5.36e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TYK2—obesity	2.41e-06	5.34e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LPL—obesity	2.39e-06	5.31e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RHOA—obesity	2.39e-06	5.3e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOS3—obesity	2.36e-06	5.24e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3R1—obesity	2.36e-06	5.24e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GPX1—obesity	2.33e-06	5.18e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CA—obesity	2.3e-06	5.11e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CA—obesity	2.29e-06	5.08e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CD36—obesity	2.27e-06	5.04e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CA—obesity	2.25e-06	5e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CB—obesity	2.23e-06	4.95e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MTOR—obesity	2.23e-06	4.95e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CB—obesity	2.18e-06	4.84e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MTOR—obesity	2.18e-06	4.84e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—MTHFR—obesity	2.15e-06	4.78e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPARA—obesity	2.11e-06	4.69e-05	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AKT1—obesity	2.07e-06	4.59e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AGT—obesity	2.05e-06	4.54e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6—obesity	2.04e-06	4.52e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6—obesity	2.03e-06	4.5e-05	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AKT1—obesity	2.03e-06	4.49e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOE—obesity	2.01e-06	4.45e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6—obesity	1.99e-06	4.42e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CAV1—obesity	1.99e-06	4.41e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOA1—obesity	1.98e-06	4.4e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MMP9—obesity	1.94e-06	4.3e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MMP9—obesity	1.9e-06	4.21e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAPK8—obesity	1.89e-06	4.18e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AKT1—obesity	1.88e-06	4.17e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AKT1—obesity	1.87e-06	4.15e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAPK8—obesity	1.84e-06	4.09e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AKT1—obesity	1.84e-06	4.08e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CG—obesity	1.81e-06	4.02e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPARG—obesity	1.75e-06	3.88e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—STAT3—obesity	1.72e-06	3.82e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—POMC—obesity	1.72e-06	3.82e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—INS—obesity	1.71e-06	3.8e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—STAT3—obesity	1.69e-06	3.74e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MYC—obesity	1.6e-06	3.55e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TGFB1—obesity	1.6e-06	3.55e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CD—obesity	1.59e-06	3.53e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALB—obesity	1.57e-06	3.48e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MYC—obesity	1.57e-06	3.48e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TGFB1—obesity	1.56e-06	3.47e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3R1—obesity	1.5e-06	3.33e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NOS3—obesity	1.5e-06	3.33e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CB—obesity	1.39e-06	3.08e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTGS2—obesity	1.37e-06	3.05e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CA—obesity	1.36e-06	3.02e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CA—obesity	1.33e-06	2.95e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6—obesity	1.2e-06	2.67e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6—obesity	1.18e-06	2.61e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKT1—obesity	1.11e-06	2.46e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKT1—obesity	1.09e-06	2.41e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CA—obesity	8.46e-07	1.88e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKT1—obesity	6.91e-07	1.53e-05	CbGpPWpGaD
